Leiting JL, Grotz TE. Advancements and challenges in treating advanced gastric cancer in the West. World J Gastrointest Oncol 2019; 11(9): 652-664 [PMID: 31558971 DOI: 10.4251/wjgo.v11.i9.652]
Corresponding Author of This Article
Travis E Grotz, MD, Assistant Professor, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN 55905, United States. grotz.travis@mayo.edu
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Improved PFS in the bevacizumab group (median survival 6.7 mo vs 5.3 mo)
Standard chemo with
Capecitabine, cisplatin,
bevacizumab
bevacizumab
REGARD
Multiple
Complete
2009-2012
VEGFR
Best supportive care
-
Improved OS in ramucirumab group (median survival 5.2 mo vs 3.8 mo)
Best supportive care
Ramucirumab
with ramucirumab
ToGA Trial
Multiple
Complete
2005-2008
HER2
Standard chemo
Cisplatin with capecitabine or 5-FU
Improved OS in the trastuzumab group (median survival 13.8 mo vs 11.1 mo)
Standard chemo with trastuzumab
Cisplatin, capecitabine or 5-FU, trastuzumab
KEYNOTE-012
Multiple
Complete
2013-2014
PD-L1
Pembrolizumab
Pembrolizumab
Median OS of 11.4 mo
GASTRICHIP (NCT01882933)
Multiple
Ongoing
-
HIPEC
Curative gastrectomy with D1-D2 lymph node dissection
-
-
Curative gastrectomy with D1-D2 lymph node dissection with HIPEC
IP Oxaliplatin with IV 5-FU and leucovorin
Citation: Leiting JL, Grotz TE. Advancements and challenges in treating advanced gastric cancer in the West. World J Gastrointest Oncol 2019; 11(9): 652-664